GSK PLC (LSE:GSK, NYSE:GSK)’s development pipeline has lots of underrated potential says Deutsche Bank, which recently hosted a meeting with most of the pharma’s top R&D executives.
Work needs to be done to rebuild the innovation proposition in the eyes of many investors, but Deutsche Bank sees clear emergent strands of underappreciated potential.
In particular, Deutsche Bank highlights the revival in oncology, where the Blenrep [Myeloma] appears to go from strength to strength.
Buy with a 1,950p target is Deutsche Bank’s view. Shares were down 0.5% at 1,738p today.